Intus Bio

About:

Intus Bio's Titan-1 platform is powering a microbiome revolution, by unlocking insights into the role of bacteria across health ouctomes

Website: https://intusbio.com/

Top Investors: UConn Innovation Fund - University of Connecticut, Connecticut Innovations

Description:

Intus Bio's breakthrough and proprietary Titan-1 platform is powering a microbiome revolution, by providing high-resolution data on a high-throughput basis. The platform is able to benefit researchers and patients alike, with its strain level data combined with advanced analysis combing for truly actionable insights and results. This platform can either be used for patient testing to help health outcomes, or for patient stratification and response prediction, study or trial de-risking and as a way to significantly improve patient safety. The company's mission is to make the microbiome as integral to healthcare as it is to our health, by generating unprecedented visibility and understanding of the bacteria in us, on us and around us.

Total Funding Amount:

$4.15M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Farmington, Connecticut, United States

Founded Date:

2015-06-01

Contact Email:

info(AT)intusbio.com

Founders:

Mark Driscoll, Paul Denslow

Number of Employees:

11-50

Last Funding Date:

2024-07-16

IPO Status:

Private

Industries:

© 2025 bioDAO.ai